Tag: GlobeNewswire

Highlights

• High-Grade^** Uranium at Surface: A prospecting, mapping, and geochemical sampling program is planned for October 2026 to expand on newly identified and historical uranium-bearing outcrops including the Manhattan showing (1.19 to 8.10% U₃O₈)² and SMDI showing 2052 (0.137% U₃O₈ and 2,300 ppm Th).³
• Integration with Drilling Results: The results of the inaugural drill program on the Project clearly outlined a robust multi-kilometre uranium-bearing mineralized system across the Manhattan, Brooklyn, and Tribeca target areas. Drilling confirmed the presence of significant fault systems linked to uranium enrichment and prospective hydrothermal alteration in the basement rock, which will be further investigated in detail at surface during the Program.
• Follow Up Targets & Next Steps: Following the integration of additional surface exploration results with drilling and geophysical datasets, a second phase drilling program is being planned to continue testing along strike of mineralized drill holes in addition to priority regional drill targets. Several priority uranium targets remain along >25 km of structural strike length.

VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — Aventis Energy Inc. (“Aventis” or the “Company”) (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is pleased to announce plans for additional ground exploration at the Corvo Uranium Project (“Corvo”, or the “Project”), currently under a three-year earn-in option agreement (the “Option Agreement”) with Standard Uranium Ltd. (TSX-V: STND) (“Standard”). Exploration crews are scheduled to mobilize to site on October 1, 2026, to begin a detailed mapping and sampling program (the “Program”) across historical uranium showings and newly identified zones of interest.

The fall 2026 Program will focus on prospective areas around and along strike of successful drilling results from the winter 2026 drill campaign. Analytical results from the Company’s first-ever drill campaign at Corvo confirmed anomalous^* uranium in all nine (9) completed drill holes. Results returned a total of fifty-five (55) metres of weakly anomalous uranium (>10 ppm U, partial), including twenty-three (23) metres of moderately anomalous uranium (>50 ppm U, partial), and including thirteen (13) metres of highly anomalous uranium (>100 ppm U, partial).¹

Michael Mulberry, Chief Executive Officer & Director of Aventis, commented, “The fall program is the natural next step following the success of our inaugural drill campaign at Corvo. With crews returning to the ground in October, we have the opportunity to tie detailed mapping and sampling directly to the structures, alteration and uranium enrichment identified in drilling, and to expand on high-grade surface showings such as Manhattan. Combined with the ongoing geophysical work, this will sharpen our drill targets ahead of the second phase of drilling planned for 2027, and we look forward to continuing to advance the Project alongside Standard Uranium.”

Figure 1. Regional map of the Corvo Project. The Project is located 45 km northeast of Atha Energy’s Gemini Mineralized Zone and 60 km due east of Cameco’s McArthur River mine.

2026 Fall Exploration Program

Standard’s technical team is scheduled to mobilize to the Project on October 1, 2026, to undertake a detailed mapping, prospecting, and sampling Program to expand on known uranium showings and collect additional geological information at surface which can be linked to drill results. Collected grab samples will be transported to Saskatchewan Research Council Geoanalytical Laboratories in Saskatoon, SK for geochemical analysis. The Company will fund the exploration Program as part of the Option Agreement dated May 8, 2025⁴ and Standard will act as operator.

Supplementary geophysical work programs across the Project are also being designed to further refine drill targets for a 2027 drill program. Ongoing geophysical interpretation and modeling is planned throughout the remainder of 2026 to integrate drilling, geophysics, and prospecting datasets, which will further derisk drill targets across the Project prior to follow-up drilling next year.

The Company believes the Project is highly prospective for the discovery of shallow, high-grade^** basement-hosted uranium mineralization akin to the Rabbit Lake deposit and the recently discovered Gemini Mineralized Zone. Located just outside the current margin of the Athabasca Basin, Corvo boasts shallow drill targets with bedrock under minimal cover of glacial till. Several outcrop showings of mineralized veins and fractures are present on the Project, notably the Manhattan Showing that returned modern sample results up to 8.10% U₃O₈ at surface².

Qualified Person Statement

The scientific and technical information contained in this news release has been reviewed and approved by Sean Hillacre, P.Geo., President and VP Exploration of Standard Uranium Ltd. and a “qualified person” as defined in NI 43-101 – Standards of Disclosure for Mineral Projects.

Samples collected for analysis were sent to SRC Geoanalytical Laboratories (“SRC”) in Saskatoon, Saskatchewan for preparation, processing, and ICP-MS multi-element analysis using total and partial digestion and boron by fusion. Basement samples were tested with ICP-MS2 uranium multi-element exploration package plus boron. All sandstone samples, and basement samples marked as radioactive upon arrival to the lab were also analyzed using the U₃O₈ assay (reported in wt.%). Basement rock split interval samples range from 0.1 to 1.0 m. SRC is an ISO/IEC 17025/2005 and Standards Council of Canada certified analytical laboratory. Blanks, standard reference materials, and repeats were inserted into the sample stream at regular intervals in accordance with Standard’s quality assurance/quality control (“QA/QC”) protocols. All samples passed internal QA/QC protocols and the results presented in this release are deemed complete, reliable, and repeatable.

Historical data disclosed in this news release relating to sampling results from previous operators are historical in nature. Neither the Company nor a qualified person has yet verified this data and therefore investors should not place undue reliance on such data. The Company’s future exploration work may include verification of the data. The Company considers historical results to be relevant as an exploration guide and to assess the mineralization as well as economic potential of exploration projects. Any historical grab samples disclosed are selected samples and may not represent true underlying mineralization.

References

¹ News Release: Standard Uranium Confirms Uranium Enrichment in all Winter 2026 Drill Holes at the Corvo Uranium Project, https://www.standarduranium.ca/news-releases/standard-uranium-confirms-uranium-enrichment-in-all-winter-2026-drill-holes-at-the-corvo-uranium-project

² News Release: Standard Uranium Confirms High-Grade Uranium Mineralization up to 8.10% U₃O₈ at Surface on the Corvo Project, https://standarduranium.ca/news-releases/standard-uranium-confirms-high-grade-uranium-mineralization-at-surface-on-the-corvo-project/

³ SMDI# 2052: https://mineraldeposits.saskatchewan.ca/Home/Viewdetails/2052 & Mineral Assessment Report MAW00047: Eagle Plains Resources Inc., 2011-2012

⁴ News Release: Standard Uranium Announces Signing of Definitive Agreement to Option Corvo Project in Eastern Athabasca Basin, https://www.standarduranium.ca/news-releases/standard-uranium-announces-signing-of-definitive-agreement-to-option-corvo-project-in-eastern-athabasca-basin

^*In crystalline basement rocks, the Company considers concentrations of uranium >10 ppm U to be “weakly anomalous”, concentrations >50 ppm U to be “moderately anomalous” and concentrations >100 ppm U to be “highly anomalous”. Intervals represent drilled core lengths; True thicknesses of mineralized zones cannot be determined with certainty at this stage of exploration.

^**The Company considers uranium mineralization with concentrations greater than 1.0 wt.% U₃O₈ to be “high-grade”.

About Aventis Energy Inc. 

Aventis Energy Inc. (CSE: AVE | FRA: C0O0 | OTC: VBAMF) is a mineral exploration company dedicated to the development of strategic projects comprised of battery, base and precious metals in stable jurisdictions. The Company is working to advance its Corvo Uranium & Sting Copper Project.

The Corvo Uranium property has historical drill holes intersected multiple intervals of uranium mineralization, notably along a strike length of 800 metres between historical drill holes TL-79-3 (0.116% U₃O₈ over 1.05 m) and TL-79-5 (0.065% U₃O₈ over 0.15 m)². High-grade* Uranium at Surface with the Manhattan showing (with outcrop samples grab samples returning up to 8.10% U₃O₈) and SMDI showing 2052 (0.137% U₃O₈ and 2,300 ppm Th).

The Sting Copper Project covers approximately 3,700 hectares and recently had results of 54.8m at 0.32% Cu starting at a depth of 27.0m, with higher-grade intervals including six samples (≥0.5m length) ranging from 0.96% to 5.43% Cu. High grade samples of 0.5m at 2.85% Cu and 0.5m at 1.92% Cu with an additional broader interval of 31.1m at 0.27% Cu.

On Behalf of the Board of Directors

Michael Mulberry
Chief Executive Officer, Director
+1 (604) 229-9772
info@vitalbatterymetals.com

Disclaimer for Forward-Looking Information

This news release includes certain “Forward-Looking Statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995 and “forward-looking information” under applicable Canadian securities laws. When used in this news release, the words “anticipate”, “believe”, “estimate”, expect”, “target”, “plan”, “forecast”, “may”, “would”, “could”, “schedule” and similar words or expressions, identify forward-looking statements or information.

Forward-looking statements and forward-looking information relating to any future mineral production, liquidity, enhanced value and capital markets profile of Aventis, future growth potential for Aventis and its business, and future exploration plans are based on management’s reasonable assumptions, estimates, expectations, analyses and opinions, which are based on management’s experience and perception of trends, current conditions and expected developments, and other factors that management believes are relevant and reasonable in the circumstances, but which may prove to be incorrect. Assumptions have been made regarding, among other things, the price of uranium, copper, gold and other metals; costs of exploration and development; the estimated costs of development of exploration projects; Aventis’ ability to operate in a safe and effective manner and its ability to obtain financing on reasonable terms.

This news release contains “forward-looking information” within the meaning of the Canadian securities laws. Statements, other than statements of historical fact, may constitute forward looking information and include, without limitation, statements with respect to the Project and its mineralization potential; the Company’s objectives, goals, or future plans with respect to the Project; further exploration work on the Project in the future; the expected benefits of completing the Program; the commencement of additional drilling program(s) on the Project in the future. With respect to the forward-looking information contained in this news release, the Company has made numerous assumptions regarding, among other things, the geological, metallurgical, engineering, financial and economic advice that the Company has received is reliable and are based upon practices and methodologies which are consistent with industry standards. While the Company considers these assumptions to be reasonable, these assumptions are inherently subject to significant uncertainties and contingencies. Additionally, there are known and unknown risk factors which could cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein. Known risk factors include, among others: fluctuations in commodity prices and currency exchange rates; uncertainties relating to interpretation of well results and the geology, continuity and grade of uranium, copper, gold and other metal deposits; uncertainty of estimates of capital and operating costs, recovery rates, production estimates and estimated economic return; the need for cooperation of government agencies in the exploration and development of properties and the issuance of required permits; the need to obtain additional financing to develop properties and uncertainty as to the availability and terms of future financing; the possibility of delay in exploration or development programs or in construction projects and uncertainty of meeting anticipated program milestones; uncertainty as to timely availability of permits and other governmental approvals; increased costs and restrictions on operations due to compliance with environmental and other requirements; increased costs affecting the metals industry and increased competition in the metals industry for properties, qualified personnel, and management. All forward-looking information herein is qualified in its entirety by this cautionary statement, and the Company disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

The Canadian Securities Exchange (CSE) does not accept responsibility for the adequacy or accuracy of this release.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/13d8d50a-3944-475c-99f7-a8c5e9da5219

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE^® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.¹

“With today’s launch, TAVALISSE^® is now available to adults in Brazil living with chronic ITP who have not responded adequately to prior therapy. TAVALISSE^® strengthens Knight’s hematology and oncology portfolio in Brazil alongside MINJUVI^® and continues our track record of bringing innovative products to physicians and patients across Latin America,” said Samira Sakhia, President and CEO of Knight Therapeutics.

Knight announced its agreement with Rigel Pharmaceuticals, Inc. in May 2022, securing exclusive rights to commercialize TAVALISSE^® in Latin America. Since entering the agreement, Knight has made significant regulatory progress throughout the region and has submitted TAVALISSE^® for regulatory approval in Brazil, Colombia, Mexico, Argentina and Paraguay and has obtained regulatory approval in Mexico in 2024, Brazil in May 2026, and Colombia in September 2026. The Company launched TAVALISSE^® in Mexico in May 2026.

About TAVALISSE^®

TAVALISSE^® (fostamatinib disodium hexahydrate) is an orally administered spleen tyrosine kinase (SYK) inhibitor. It is currently marketed in the United States under the brand name TAVALISSE (100mg and 150mg tablets) and in Europe under the brand name TAVLESSE for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.²

TAVALISSE^® is a registered trademark of Rigel Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

About Chronic Immune Thrombocytopenia (ITP)

In patients with ITP, the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding.³ People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death.⁴

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. ANVISA, Prescribing Information. Approved on May 7, 2026.
2. Tavalisse. Full Prescribing Information. Rigel Pharmaceuticals, 2018, www.tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf.
3. National Heart, Lung, and Blood Institute. Immune Thrombocytopenia. U.S. Department of Health and Human Services, https://www.nhlbi.nih.gov/health/immune-thrombocytopenia. Accessed 24 July 2025.
4. Kos, Marek et al. “The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.” Journal of clinical medicine vol. 13,22 6738. 8 Nov. 2024, doi:10.3390/jcm13226738

CONTACT INFORMATION FOR KNIGHT:
Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia	Arvind Utchanah
President & Chief Executive Officer	Chief Financial Officer
T: 514.484.4483	T: 514.484.4483
Email: IR@knighttx.com	Email: IR@knighttx.com
Website: www.knighttx.com	Website: www.knighttx.com

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE^® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.¹

“With today’s launch, TAVALISSE^® is now available to adults in Brazil living with chronic ITP who have not responded adequately to prior therapy. TAVALISSE^® strengthens Knight’s hematology and oncology portfolio in Brazil alongside MINJUVI^® and continues our track record of bringing innovative products to physicians and patients across Latin America,” said Samira Sakhia, President and CEO of Knight Therapeutics.

Knight announced its agreement with Rigel Pharmaceuticals, Inc. in May 2022, securing exclusive rights to commercialize TAVALISSE^® in Latin America. Since entering the agreement, Knight has made significant regulatory progress throughout the region and has submitted TAVALISSE^® for regulatory approval in Brazil, Colombia, Mexico, Argentina and Paraguay and has obtained regulatory approval in Mexico in 2024, Brazil in May 2026, and Colombia in September 2026. The Company launched TAVALISSE^® in Mexico in May 2026.

About TAVALISSE^®

TAVALISSE^® (fostamatinib disodium hexahydrate) is an orally administered spleen tyrosine kinase (SYK) inhibitor. It is currently marketed in the United States under the brand name TAVALISSE (100mg and 150mg tablets) and in Europe under the brand name TAVLESSE for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.²

TAVALISSE^® is a registered trademark of Rigel Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

About Chronic Immune Thrombocytopenia (ITP)

In patients with ITP, the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding.³ People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death.⁴

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. ANVISA, Prescribing Information. Approved on May 7, 2026.
2. Tavalisse. Full Prescribing Information. Rigel Pharmaceuticals, 2018, www.tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf.
3. National Heart, Lung, and Blood Institute. Immune Thrombocytopenia. U.S. Department of Health and Human Services, https://www.nhlbi.nih.gov/health/immune-thrombocytopenia. Accessed 24 July 2025.
4. Kos, Marek et al. “The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.” Journal of clinical medicine vol. 13,22 6738. 8 Nov. 2024, doi:10.3390/jcm13226738

CONTACT INFORMATION FOR KNIGHT:
Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia	Arvind Utchanah
President & Chief Executive Officer	Chief Financial Officer
T: 514.484.4483	T: 514.484.4483
Email: IR@knighttx.com	Email: IR@knighttx.com
Website: www.knighttx.com	Website: www.knighttx.com

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) — Knight Therapeutics Inc. (“Knight”) (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today the launch of TAVALISSE^® (fostamatinib disodium hexahydrate) in Brazil, for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.¹

“With today’s launch, TAVALISSE^® is now available to adults in Brazil living with chronic ITP who have not responded adequately to prior therapy. TAVALISSE^® strengthens Knight’s hematology and oncology portfolio in Brazil alongside MINJUVI^® and continues our track record of bringing innovative products to physicians and patients across Latin America,” said Samira Sakhia, President and CEO of Knight Therapeutics.

Knight announced its agreement with Rigel Pharmaceuticals, Inc. in May 2022, securing exclusive rights to commercialize TAVALISSE^® in Latin America. Since entering the agreement, Knight has made significant regulatory progress throughout the region and has submitted TAVALISSE^® for regulatory approval in Brazil, Colombia, Mexico, Argentina and Paraguay and has obtained regulatory approval in Mexico in 2024, Brazil in May 2026, and Colombia in September 2026. The Company launched TAVALISSE^® in Mexico in May 2026.

About TAVALISSE^®

TAVALISSE^® (fostamatinib disodium hexahydrate) is an orally administered spleen tyrosine kinase (SYK) inhibitor. It is currently marketed in the United States under the brand name TAVALISSE (100mg and 150mg tablets) and in Europe under the brand name TAVLESSE for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.²

TAVALISSE^® is a registered trademark of Rigel Pharmaceuticals, Inc. All other trademarks are the property of their respective owners.

About Chronic Immune Thrombocytopenia (ITP)

In patients with ITP, the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. Common symptoms of ITP are excessive bruising and bleeding.³ People suffering with chronic ITP may live with an increased risk of severe bleeding events that can result in serious medical complications or even death.⁴

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a pharmaceutical company focused on acquiring, in-licensing and commercializing pharmaceutical products for Canada and Latin America. Knight’s Latin American subsidiaries operate under United Medical, Biotoscana Farma and Laboratorio LKM. Knight Therapeutics Inc.’s shares trade on TSX under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company’s web site at www.knighttx.com or www.sedarplus.ca.

Forward-Looking Statements for Knight

This document contains forward-looking statements for Knight Therapeutics Inc. and its subsidiaries. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. Knight Therapeutics Inc. considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared but cautions the reader that these assumptions regarding future events, many of which are beyond the control of Knight Therapeutics Inc. and its subsidiaries, may ultimately prove to be incorrect. Factors and risks which could cause actual results to differ materially from current expectations are discussed in Knight Therapeutics Inc.’s Annual Report and in Knight Therapeutics Inc.’s Annual Information Form for the year ended December 31, 2025, as filed on www.sedarplus.ca. Knight Therapeutics Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information or future events, except as required by law.

References

1. ANVISA, Prescribing Information. Approved on May 7, 2026.
2. Tavalisse. Full Prescribing Information. Rigel Pharmaceuticals, 2018, www.tavalisse.com/downloads/pdf/Tavalisse-Full-Prescribing-Information.pdf.
3. National Heart, Lung, and Blood Institute. Immune Thrombocytopenia. U.S. Department of Health and Human Services, https://www.nhlbi.nih.gov/health/immune-thrombocytopenia. Accessed 24 July 2025.
4. Kos, Marek et al. “The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.” Journal of clinical medicine vol. 13,22 6738. 8 Nov. 2024, doi:10.3390/jcm13226738

CONTACT INFORMATION FOR KNIGHT:
Investor Contact:
Knight Therapeutics Inc.
Samira Sakhia	Arvind Utchanah
President & Chief Executive Officer	Chief Financial Officer
T: 514.484.4483	T: 514.484.4483
Email: IR@knighttx.com	Email: IR@knighttx.com
Website: www.knighttx.com	Website: www.knighttx.com

PHILADELPHIA and VANCOUVER, British Columbia, Oct. 06, 2026 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, and its majority-owned subsidiary, BriaPro Therapeutics Corp. (“BriaPro”), today announced that four abstracts featuring preclinical research from their respective immunotherapy programs have been selected for poster presentations at the Society for Immunotherapy of Cancer (SITC) 41^th Anniversary Annual Meeting, taking place November 4-8, 2026, in Phoenix, AZ.

The presentations will feature BriaCell’s personalized off-the-shelf immunotherapy, Bria-OTS+™ and BriaPro’s research on tumor-targeted checkpoint inhibitors, soluble CD80 (BP-80), and engineered CD80 variants.

Presentation details are listed below.

BriaCell

Title: A Multifaceted Genetically Engineered Whole-Cell Vaccine Platform Generates Potent, Broad, Persistent, and Effector-Centric Anti-Tumor Immunity Across Multiple Cancer Indications
Abstract Number: 863
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026

BriaPro

Title: Development of BP-80, a soluble CD80 dimer (CD80-Fc) for cancer treatment
Abstract Number: 404
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026

Title: Tumor-targeted checkpoint inhibitors for reactivation of tumor-infiltrating lymphocytes
Abstract Number: 405
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Friday, Nov. 6, 2026

Title: Molecular design of CD80 variants with increased affinity for PD-L1 and wild-type or lower affinity for CD28
Abstract Number: 406
Location: PCC-North Building-Lower Level-Exhibition Halls 4-5-6
Date: Saturday, Nov. 7, 2026

Following the presentation, copies of the posters will be made available at https://briacell.com/scientific-publications/.

About BriaCell Therapeutics Corp.

BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.

About BriaPro Therapeutics Corp.

BriaPro is a pre-clinical stage immunotherapy company developing binding agents and proteins with the intention to boost the ability of the body’s own cancer-fighting cells to destroy cancerous tumors.

Safe Harbor

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell and BriaPro presenting posters at the SITC 2026 Annual Meeting, and the contents of such posters, are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company’s most recent Management’s Discussion and Analysis, under the heading “Risk Factors” in the Company’s most recent Annual Information Form, and under “Risks and Uncertainties” in the Company’s other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company’s profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information

Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com

Investor Relations Contact:
investors@briacell.com

New Holiday Program Builds on Three Recent Distribution Center Wins and Expands Edible Garden’s Strategic Presence Across the Midwest, Mid-Atlantic and Northeast

BELVIDERE, NJ, Oct. 06, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that it has been awarded a new fresh herb program with Walmart for the upcoming Thanksgiving through New Year holiday season.

The new holiday program represents incremental business in addition to Edible Garden’s significant existing Walmart distribution and three recently awarded Walmart distribution centers, further expanding the Company’s relationship with one of the world’s largest retailers. Together, these awards strengthen Edible Garden’s position across the Midwest, Mid-Atlantic and Northeast, strategically important markets where the Company believes the combination of Walmart’s substantial retail presence and Edible Garden’s growing fresh herb platform creates a meaningful opportunity to capture additional market share.

The holiday program is designed to meet increased consumer demand during one of the most important selling periods of the year for fresh herbs, as holiday cooking typically drives demand for many of Edible Garden’s core offerings, including rosemary, sage, thyme, parsley, and poultry-blend herbs. Edible Garden is working closely with Walmart on the holiday program across product assortment, production planning, packaging, merchandising, logistics, and replenishment, and preparations for the season are already underway.

To support the new program and the Company’s growing Walmart distribution footprint, Edible Garden plans to leverage its vertically integrated production facilities, strategically located contract grower network, advanced demand-planning capabilities, and proprietary GreenThumb 2.0 technology. Together, these capabilities are designed to provide the flexibility and dependable fulfillment required during periods of elevated demand.

“This award is particularly significant because it represents new business layered onto our already substantial Walmart distribution and follows three recent distribution center wins,” said Jim Kras, Chief Executive Officer of Edible Garden. “Collectively, these programs are strengthening Edible Garden’s position across the Midwest, Mid-Atlantic and Northeast and expanding our participation in some of Walmart’s most important markets. We believe that growing geographic alignment creates an opportunity for both Walmart and Edible Garden to capture additional fresh herb market share while providing consumers with fresher, locally sourced products.

“The Thanksgiving-through-New Year period is one of the most demanding periods of the fresh herb calendar, and our industry-leading fulfillment rate demonstrates our ability to execute at scale. We believe Walmart’s continued expansion of our programs validates the investments we have made in production, distribution, and GreenThumb technology, while deepening our relationship with Walmart and further establishing Edible Garden as a trusted, scalable supply-chain partner to major retailers.”

Edible Garden’s GreenThumb 2.0 platform, together with its network of Company-operated facilities and strategically located contract growers, is designed to more closely align production with anticipated retail demand. This data-driven, localized approach supports the Company’s Zero-Waste Inspired® strategy by helping maintain product freshness and availability while reducing food miles, excess inventory, and shrink throughout the supply chain.

Key Performance Indicator

This press release contains reference to the Company’s fulfillment rate, which is a key performance metric management uses to analyze and measure the Company’s financial performance and results of operation. Management uses fulfillment rate as a measure of current and future business and financial performance, and it may not be comparable with measures provided by other companies. The Company defines fulfillment rate as the percentage of orders filled in full, relative to the total number of orders received during the period.

ABOUT EDIBLE GARDEN^®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired^® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way^® and Vitamin Whey^®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believe,” “expect,” “intend,” “plan,” “expand,” “advance,” “designed to,” “opportunity,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements include, without limitation, statements regarding the Company’s holiday fresh herb program with Walmart, the expected benefits of the Company’s recent Walmart distribution center awards, the Company’s ability to expand its presence and capture additional market share in its key markets, the Company’s available capacity and ability to service additional retail volume, the Company’s ability to deepen its relationship with Walmart and other major retailers, the development of the Company’s ready-to-drink manufacturing facility in Webster City, Iowa, and the Company’s Farm-to-Formula® strategy. There can be no assurance that the holiday program or the Company’s distribution center awards will result in the anticipated volume, revenue or market share gains. Forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including those described in the “Risk Factors” section and other sections of the Company’s reports filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
EDBL@crescendo-ir.com

New Holiday Program Builds on Three Recent Distribution Center Wins and Expands Edible Garden’s Strategic Presence Across the Midwest, Mid-Atlantic and Northeast

BELVIDERE, NJ, Oct. 06, 2026 (GLOBE NEWSWIRE) — Edible Garden AG Incorporated (“Edible Garden” or the “Company”) (Nasdaq: EDBL, EDBLW), a leader in controlled environment agriculture (CEA), organic and sustainable produce, and developer of the Zero-Waste Inspired® mission and Farm-to-Formula® platform, today announced that it has been awarded a new fresh herb program with Walmart for the upcoming Thanksgiving through New Year holiday season.

The new holiday program represents incremental business in addition to Edible Garden’s significant existing Walmart distribution and three recently awarded Walmart distribution centers, further expanding the Company’s relationship with one of the world’s largest retailers. Together, these awards strengthen Edible Garden’s position across the Midwest, Mid-Atlantic and Northeast, strategically important markets where the Company believes the combination of Walmart’s substantial retail presence and Edible Garden’s growing fresh herb platform creates a meaningful opportunity to capture additional market share.

The holiday program is designed to meet increased consumer demand during one of the most important selling periods of the year for fresh herbs, as holiday cooking typically drives demand for many of Edible Garden’s core offerings, including rosemary, sage, thyme, parsley, and poultry-blend herbs. Edible Garden is working closely with Walmart on the holiday program across product assortment, production planning, packaging, merchandising, logistics, and replenishment, and preparations for the season are already underway.

To support the new program and the Company’s growing Walmart distribution footprint, Edible Garden plans to leverage its vertically integrated production facilities, strategically located contract grower network, advanced demand-planning capabilities, and proprietary GreenThumb 2.0 technology. Together, these capabilities are designed to provide the flexibility and dependable fulfillment required during periods of elevated demand.

“This award is particularly significant because it represents new business layered onto our already substantial Walmart distribution and follows three recent distribution center wins,” said Jim Kras, Chief Executive Officer of Edible Garden. “Collectively, these programs are strengthening Edible Garden’s position across the Midwest, Mid-Atlantic and Northeast and expanding our participation in some of Walmart’s most important markets. We believe that growing geographic alignment creates an opportunity for both Walmart and Edible Garden to capture additional fresh herb market share while providing consumers with fresher, locally sourced products.

“The Thanksgiving-through-New Year period is one of the most demanding periods of the fresh herb calendar, and our industry-leading fulfillment rate demonstrates our ability to execute at scale. We believe Walmart’s continued expansion of our programs validates the investments we have made in production, distribution, and GreenThumb technology, while deepening our relationship with Walmart and further establishing Edible Garden as a trusted, scalable supply-chain partner to major retailers.”

Edible Garden’s GreenThumb 2.0 platform, together with its network of Company-operated facilities and strategically located contract growers, is designed to more closely align production with anticipated retail demand. This data-driven, localized approach supports the Company’s Zero-Waste Inspired® strategy by helping maintain product freshness and availability while reducing food miles, excess inventory, and shrink throughout the supply chain.

Key Performance Indicator

This press release contains reference to the Company’s fulfillment rate, which is a key performance metric management uses to analyze and measure the Company’s financial performance and results of operation. Management uses fulfillment rate as a measure of current and future business and financial performance, and it may not be comparable with measures provided by other companies. The Company defines fulfillment rate as the percentage of orders filled in full, relative to the total number of orders received during the period.

ABOUT EDIBLE GARDEN^®

Edible Garden AG Incorporated is a leader in controlled environment agriculture (CEA), delivering organic, better-for-you, sustainable produce and products through its Zero-Waste Inspired^® next-generation farming model. Available in over 6,000 retail locations across the United States, Caribbean, and South America, Edible Garden is at the forefront of the CEA and sustainability technology movement, distinguished by its advanced safety-in-farming protocols, sustainable packaging, patented GreenThumb software, and innovative Self-Watering in-store displays. The Company operates state-of-the-art, vertically integrated greenhouses and processing facilities, including Edible Garden Heartland in Grand Rapids, Michigan; Edible Garden Prairie Hills in Webster City, Iowa; and its headquarters at Edible Garden Belvidere in New Jersey. It also partners with a network of contract growers strategically located near major U.S. markets to ensure freshness and reduce environmental impact. The Company is also expanding its Prairie Hills facility in Webster City, Iowa, into a dedicated ready-to-drink (RTD) clean nutrition manufacturing hub, supporting its Farm-to-Formula® strategy and its transformation into higher-margin, shelf-stable nutrition categories.

Edible Garden’s proprietary GreenThumb 2.0 software—protected by U.S. Patents US 11,158,006 B1, US 11,410,249 B2, and US 11,830,088 B2—optimizes vertical and traditional greenhouse growing conditions while aiming to reduce food miles. Its patented Self-Watering display (U.S. Patent No. D1,010,365) is designed to extend plant shelf life and elevate in-store presentation. In addition to its core CEA operations, Edible Garden owns three patents in advanced aquaculture technologies: a closed-loop shrimp farming system (US 6,615,767 B1), a modular recirculating aquaculture setup with automated water treatment and feeding (US 10,163,199 B2), and a sensor-driven ammonia control method utilizing electrolytic chlorine generation (US 11,297,809 B1).

The Company has been recognized as a FoodTech 500 firm by Forward Fooding, is a multi-year participant in Walmart’s Project Gigaton and a Giga Guru designee and has received NRG’s Excellence in Energy Award for its commitment to measurable environmental performance and energy stewardship. Edible Garden also develops and markets a growing line of nutrition and specialty food products, including Vitamin Way^® and Vitamin Whey^®—plant and whey protein powders—and Kick. Sports Nutrition, a premium performance line for health-conscious athletes seeking cleaner, better-for-you options. The Company’s offerings further include fresh, sustainable condiments such as Pulp fermented gourmet and chili-based sauces, as well as Pickle Party, a collection of fermented fresh pickles and krauts.

Learn more at https://ediblegardenag.com.
For Pulp products, visit https://www.pulpflavors.com.
For Vitamin Whey® products, visit https://vitaminwhey.com.
For Kick. Sports Nutrition products, visit https://kicksportsnutrition.net/.
Watch the Company’s latest corporate video here.

FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believe,” “expect,” “intend,” “plan,” “expand,” “advance,” “designed to,” “opportunity,” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. These statements include, without limitation, statements regarding the Company’s holiday fresh herb program with Walmart, the expected benefits of the Company’s recent Walmart distribution center awards, the Company’s ability to expand its presence and capture additional market share in its key markets, the Company’s available capacity and ability to service additional retail volume, the Company’s ability to deepen its relationship with Walmart and other major retailers, the development of the Company’s ready-to-drink manufacturing facility in Webster City, Iowa, and the Company’s Farm-to-Formula® strategy. There can be no assurance that the holiday program or the Company’s distribution center awards will result in the anticipated volume, revenue or market share gains. Forward-looking statements are based on the Company’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including those described in the “Risk Factors” section and other sections of the Company’s reports filed with the Securities and Exchange Commission. All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no duty to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Contacts:
Crescendo Communications, LLC
212-671-1020
EDBL@crescendo-ir.com

Q3 2026 ending cash expected to increase more than 50% versus Q2 2026

Pending HEI launch expected to expand Beeline’s home-finance offerings with a new product less tied to interest rates

PROVIDENCE, R.I. , Oct. 06, 2026 (GLOBE NEWSWIRE) — via IBN — Beeline Holdings, Inc. (NASDAQ: BLNE) (“Beeline” or the “Company”), a digital mortgage platform redefining the path to homeownership and property investment, today provided a preliminary update on its third-quarter 2026 performance and announced the pending launch of a Home Equity Investment (“HEI”) product as the Company continues to expand its product offering and reduce its dependence on traditional mortgage market cycles and volatile interest rates.  

Based on preliminary results, Beeline expects Q3 2026 revenue to be the second-highest quarterly revenue in Company history  and the highest since 2021, while achieving the highest margins in Company history.

The Company expects its Q3 2026 net loss to be lower than the second quarter 2026 net loss. The Company also expects its Q3 2026 adjusted EBITDA loss to improve to the lowest level in 5 years reflecting continued improvement in operating performance despite a mortgage environment challenged by elevated interest rates.

In addition, Beeline expects to end Q3 2026 with a cash position at least 50% higher than at the end of Q2 2026.

Management believes these results demonstrate the impact of Beeline’s strategic decision in April to shift its mortgage product mix toward Non-QM lending, particularly DSCR and Bank Statement loans serving property investors and self-employed borrowers.

“Q3 is expected to demonstrate that the strategic changes we made beginning in April are working,” said Nick Liuzza, CEO and Co-Founder of Beeline. “We expect to deliver the second-highest revenue quarter in our history and our highest margins ever and our lowest adjusted EBITDA loss since 2021, while strengthening our cash position. We believe the shift toward Non-QM was the right decision, and the results are beginning to demonstrate why.”

Liuzza continued, “Now we are preparing to add another significant growth opportunity with HEI. Homeowners have accumulated substantial equity, but higher interest rates can make accessing that equity through a traditional cash-out refinance or HELOC less attractive or, for some homeowners, unavailable. HEI gives us another way to serve those customers by providing access to home equity without a traditional loan or monthly principal and interest payment. Importantly, it also expands Beeline into a product category that is less directly tied to mortgage rates.”

Building Beyond the Traditional Mortgage Cycle

HEIs are growing in popularity, with more than $4 billion funded in the U.S. to date and institutional capital and securitization activity continuing to expand. Beeline’s model follows a mortgage-style process that incorporates applicable disclosures and documentation requirements, with the goal of providing a transparent, compliant and consumer-friendly experience.

Beeline is offering a HEI designed to provide homeowners with access to their home equity without traditional income documentation or required monthly payments. Structured as a loan, the HEI may have a 10-year term or align with the remaining term of the homeowner’s existing mortgage. Qualification requirements are generally less restrictive than those of a traditional mortgage, with credit scores as low as 500 potentially eligible in certain circumstances.

Management believes the emerging HEI category represents a significant opportunity as homeowners hold substantial accumulated equity while many remain reluctant to refinance existing low-rate mortgages or may not qualify for traditional home-equity financing.

By combining its growing Non-QM mortgage business with HEI, Beeline is building a broader home-finance platform designed to perform across different interest-rate environments.

“Our objective is to build a company that does not need interest rates to fall in order to grow,” Liuzza said. “Non-QM is already broadening our opportunity, and HEI gives us another large addressable market that is not driven by the same interest-rate dynamics as traditional mortgages. We believe the combination positions Beeline to continue building momentum regardless of where mortgage rates move.”

The Company will provide complete third quarter 2026 financial results in the Form 10-Q with full details, including the required reconciliations of non-GAAP to GAAP financial measures. The forecasts contained in this press release are subject to the completion of quarter-end financial close and auditor review processes and any adjustments which result therefrom.

About Beeline Holdings, Inc.

Beeline Holdings, Inc. (NASDAQ: BLNE) is a technology-driven mortgage and home-finance company focused on simplifying and accelerating the path to homeownership, property investment and home-equity access. Through its digital platform, Beeline offers mortgage products designed for traditional borrowers, self-employed borrowers and real estate investors and is expanding its platform into home equity investment products.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding preliminary third-quarter financial results, expected revenue, margins, third quarter 2026 loss, adjusted EBITDA, cash position, the anticipated benefits of Beeline’s Non-QM strategy, the pending launch and potential growth and benefits of its HEI product.

Forward-looking statements are prefaced by words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “should,” “would,” “intend,” “seem,” “potential,” “appear,” “continue,” “future,” “believe,” “estimate,” “forecast,” “project,” “target,” and similar words. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. We caution you, therefore, against relying on any of these forward-looking statements. Our actual results may differ materially from those contemplated by the forward-looking statements for a variety of reasons, including, without limitation, the possibility that estimates, projections and assumptions on which the forward-looking statements are based prove to be incorrect including our revenue or operating results being less than expected  and adjustments that may result from financial statement close and auditor review processes,  future interest rate changes, the risks arising from the impact of affordability, inflation, tariffs, the war in the Middle East, and a recession which may result on the Company’s business, prospective customers, and on the national and global economy, our need for additional capital to meet future goals and milestone targets, our ability to attract homeowners to our products and services, our ability to comply with applicable regulatory requirements and new regulations and developments that may arise including the potential for regulatory changes regarding digital assets, artificial intelligence, and other areas that impact and may in the future impact the Company’s business, the possibility that our expectations and perceived benefits with respect to strategic transactions, and the risk that software and technology infrastructure on which we depend fails to perform as designed or intended. Additional information regarding these and other risks is contained in Beeline’s filings with the Securities and Exchange Commission, including the Risk Factors contained in the Company’s 2025 Annual Report on Form 10-K and our prospectus supplement dated March 10, 2026. Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Contacts

Investor Relations

ir@makeabeeline.com

Media Inquiries

press@makeabeeline.com

Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

Q3 2026 ending cash expected to increase more than 50% versus Q2 2026

Pending HEI launch expected to expand Beeline’s home-finance offerings with a new product less tied to interest rates

PROVIDENCE, R.I. , Oct. 06, 2026 (GLOBE NEWSWIRE) — via IBN — Beeline Holdings, Inc. (NASDAQ: BLNE) (“Beeline” or the “Company”), a digital mortgage platform redefining the path to homeownership and property investment, today provided a preliminary update on its third-quarter 2026 performance and announced the pending launch of a Home Equity Investment (“HEI”) product as the Company continues to expand its product offering and reduce its dependence on traditional mortgage market cycles and volatile interest rates.  

Based on preliminary results, Beeline expects Q3 2026 revenue to be the second-highest quarterly revenue in Company history  and the highest since 2021, while achieving the highest margins in Company history.

The Company expects its Q3 2026 net loss to be lower than the second quarter 2026 net loss. The Company also expects its Q3 2026 adjusted EBITDA loss to improve to the lowest level in 5 years reflecting continued improvement in operating performance despite a mortgage environment challenged by elevated interest rates.

In addition, Beeline expects to end Q3 2026 with a cash position at least 50% higher than at the end of Q2 2026.

Management believes these results demonstrate the impact of Beeline’s strategic decision in April to shift its mortgage product mix toward Non-QM lending, particularly DSCR and Bank Statement loans serving property investors and self-employed borrowers.

“Q3 is expected to demonstrate that the strategic changes we made beginning in April are working,” said Nick Liuzza, CEO and Co-Founder of Beeline. “We expect to deliver the second-highest revenue quarter in our history and our highest margins ever and our lowest adjusted EBITDA loss since 2021, while strengthening our cash position. We believe the shift toward Non-QM was the right decision, and the results are beginning to demonstrate why.”

Liuzza continued, “Now we are preparing to add another significant growth opportunity with HEI. Homeowners have accumulated substantial equity, but higher interest rates can make accessing that equity through a traditional cash-out refinance or HELOC less attractive or, for some homeowners, unavailable. HEI gives us another way to serve those customers by providing access to home equity without a traditional loan or monthly principal and interest payment. Importantly, it also expands Beeline into a product category that is less directly tied to mortgage rates.”

Building Beyond the Traditional Mortgage Cycle

HEIs are growing in popularity, with more than $4 billion funded in the U.S. to date and institutional capital and securitization activity continuing to expand. Beeline’s model follows a mortgage-style process that incorporates applicable disclosures and documentation requirements, with the goal of providing a transparent, compliant and consumer-friendly experience.

Beeline is offering a HEI designed to provide homeowners with access to their home equity without traditional income documentation or required monthly payments. Structured as a loan, the HEI may have a 10-year term or align with the remaining term of the homeowner’s existing mortgage. Qualification requirements are generally less restrictive than those of a traditional mortgage, with credit scores as low as 500 potentially eligible in certain circumstances.

Management believes the emerging HEI category represents a significant opportunity as homeowners hold substantial accumulated equity while many remain reluctant to refinance existing low-rate mortgages or may not qualify for traditional home-equity financing.

By combining its growing Non-QM mortgage business with HEI, Beeline is building a broader home-finance platform designed to perform across different interest-rate environments.

“Our objective is to build a company that does not need interest rates to fall in order to grow,” Liuzza said. “Non-QM is already broadening our opportunity, and HEI gives us another large addressable market that is not driven by the same interest-rate dynamics as traditional mortgages. We believe the combination positions Beeline to continue building momentum regardless of where mortgage rates move.”

The Company will provide complete third quarter 2026 financial results in the Form 10-Q with full details, including the required reconciliations of non-GAAP to GAAP financial measures. The forecasts contained in this press release are subject to the completion of quarter-end financial close and auditor review processes and any adjustments which result therefrom.

About Beeline Holdings, Inc.

Beeline Holdings, Inc. (NASDAQ: BLNE) is a technology-driven mortgage and home-finance company focused on simplifying and accelerating the path to homeownership, property investment and home-equity access. Through its digital platform, Beeline offers mortgage products designed for traditional borrowers, self-employed borrowers and real estate investors and is expanding its platform into home equity investment products.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding preliminary third-quarter financial results, expected revenue, margins, third quarter 2026 loss, adjusted EBITDA, cash position, the anticipated benefits of Beeline’s Non-QM strategy, the pending launch and potential growth and benefits of its HEI product.

Forward-looking statements are prefaced by words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “should,” “would,” “intend,” “seem,” “potential,” “appear,” “continue,” “future,” “believe,” “estimate,” “forecast,” “project,” “target,” and similar words. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. We caution you, therefore, against relying on any of these forward-looking statements. Our actual results may differ materially from those contemplated by the forward-looking statements for a variety of reasons, including, without limitation, the possibility that estimates, projections and assumptions on which the forward-looking statements are based prove to be incorrect including our revenue or operating results being less than expected  and adjustments that may result from financial statement close and auditor review processes,  future interest rate changes, the risks arising from the impact of affordability, inflation, tariffs, the war in the Middle East, and a recession which may result on the Company’s business, prospective customers, and on the national and global economy, our need for additional capital to meet future goals and milestone targets, our ability to attract homeowners to our products and services, our ability to comply with applicable regulatory requirements and new regulations and developments that may arise including the potential for regulatory changes regarding digital assets, artificial intelligence, and other areas that impact and may in the future impact the Company’s business, the possibility that our expectations and perceived benefits with respect to strategic transactions, and the risk that software and technology infrastructure on which we depend fails to perform as designed or intended. Additional information regarding these and other risks is contained in Beeline’s filings with the Securities and Exchange Commission, including the Risk Factors contained in the Company’s 2025 Annual Report on Form 10-K and our prospectus supplement dated March 10, 2026. Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Contacts

Investor Relations

ir@makeabeeline.com

Media Inquiries

press@makeabeeline.com

Corporate Communications:
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

GRAND FALLS-WINDSOR, Newfoundland and Labrador, Oct. 06, 2026 (GLOBE NEWSWIRE) — First Atlantic Nickel & Cobalt Corp. (TSXV: FAN) (OTCQB: FANCF) (FSE: P210) (“First Atlantic” or the “Company”) is pleased to announce that it has closed a no-warrant, non-brokered private placement (the “Offering”) for aggregate gross proceeds of $3,492,000.90. Following this closing, the Company has raised aggregate gross proceeds of approximately $13.4 million from financings completed since September 2026. The Offering consisted of 4,207,230 flow-through common shares of the Company (each, an “FT Share”) issued at a price of $0.83 per FT Share. The price of $0.83 per FT Share represents a premium of approximately 22% to the closing price of the Company’s common shares on the TSX Venture Exchange (the “Exchange”) on October 5, 2026. Each FT Share qualifies as a “flow-through share” within the meaning of subsection 66(15) of the Income Tax Act (Canada). No warrants were issued in connection with the Offering.

“Since September, First Atlantic has raised approximately $13.4 million, including this $3.49 million financing, a very significant development for the Pipestone XL Nickel-Cobalt Alloy Project that will accelerate our exploration and mining development. The funds allow us to significantly expand drilling at Alloy Max and the RPM Zone, drill new targets along the 30-kilometre trend that have never been tested, and develop the exploration access road north toward Atlantic Lake, opening areas that until now could only be reached by helicopter.”

“North America has limited smelting capacity to meet future nickel and cobalt demand. Pipestone XL is a significant, large-scale ophiolite complex approximately 30 kilometres long, where awaruite occurs disseminated in the ultramafic host rock over large areas. It has the potential to be a large source of both metals without smelting, moving directly into downstream refining and bypassing that midstream processing constraint. It is a scalable, environmentally sustainable solution that supports a resilient supply chain and reduces reliance on foreign offshore smelting.”

Adrian Smith, P.Geo., CEO of First Atlantic Nickel & Cobalt Corp.

First Atlantic welcomes calls directly from shareholders and prospective investors. For questions about the Company or the Pipestone XL project, or simply to learn more, investors are invited to call Rob Guzman, Investor Relations, at +1-844-592-6337 or email rob@fanickel.com.

This funding will allow the Company to significantly expand exploration and infill drilling at the Alloy Max and RPM Zones. It will also allow the Company to drill new, previously untested targets and areas of the project that have never been drilled.

The funding will also allow the Company to develop the full exploration access road that will eventually connect Grand Falls-Windsor to the historic Atlantic Lake Zone, designed to follow the magnetic anomaly further north inside the 30-kilometre nickel trend of the Pipestone Ophiolite Complex. As the road is developed, exploration and bedrock stripping along the route will test for additional occurrences of visible awaruite and potential new drill targets, as the Company aims to develop a multi-pit resource at the Pipestone XL Nickel-Cobalt Alloy Project. In each case, these expenditures will be funded only to the extent they qualify as Qualifying Expenditures (as defined below).

PIPESTONE XL: A DISTRICT-SCALE NICKEL-COBALT ALLOY PROJECT

Pipestone XL is First Atlantic’s wholly owned, district-scale project spanning the entire 30-kilometre Pipestone Ophiolite Complex in central Newfoundland, a belt of ultramafic rock enriched in nickel, cobalt, and chromium. The Project hosts multiple zones of awaruite (Ni₃Fe) mineralization, including RPM, Alloy Max, Super Gulp, Atlantic Lake, and Chrome Pond. The RPM Zone is the most advanced, with drilling having outlined magnetically recoverable awaruite over more than 1.2 kilometres of strike and more than 800 metres of width. Drilling is ongoing at Alloy Max, a second large-scale zone spanning approximately 4 kilometres of strike and up to 1.5 kilometres in width, making it larger than the RPM Zone.

Awaruite at Pipestone XL is the product of serpentinization, which drove sulphur out of the system and left a sulphur-free alloy which carries no acid mine drainage risk and can be concentrated by the Company’s ONSHORE MAX™ process without smelting, roasting, or high-pressure acid leaching. This smelter-free pathway addresses the midstream bottleneck in North America, where the United States has no operating nickel smelters and only two remain in Canada, and supports a vertically integrated supply chain moving directly from mine to downstream battery refining, stainless steel and specialty alloy production. The Company is also evaluating secondary chromium mineralization as a potential co-product, along with low-carbon Engineered Mineral Hydrogen (EMH) in partnership with VEMA Hydrogen¹. Investors can learn more about VEMA’s Engineered Mineral Hydrogen at https://www.vema.earth.

Figure 1: Map showing multiple target zones across the 30-kilometer nickel trend over total magnetic intensity (TMI) at the Pipestone XL Project highlighting the showing, the 30-kilometre Pipestone Ophiolite Complex and the RPM, Alloy Max, Super Gulp, Atlantic Lake and Chrome Pond Zones.

Pipestone XL is located in an established infrastructure corridor with year-round road access, nearby high-voltage transmission and clean hydroelectric power from the Bay d’Espoir generating station. It is also located approximately 200 kilometres from Gander International Airport and Vale’s Long Harbour nickel processing plant. This positioning aligns with growing U.S. and allied policy focus on critical mineral supply chains, including nickel’s addition to the U.S. critical minerals list in 2022, the January 2026 White House proclamation on processed critical minerals², the Company’s acceptance into the U.S. Defense Industrial Base Consortium³, and the June 2026 G7 Leaders’ Declaration naming nickel one of two pilot critical minerals for allied investment and offtake⁴.

Newfoundland and Labrador is consistently recognized as one of the world’s leading mining jurisdictions in the Fraser Institute’s Annual Survey of Mining Companies, ranking 7th globally on the Policy Perception Index in the most recent survey, published in February 2026, and placing in the global top 10 for overall investment attractiveness in each of the three prior surveys. Pipestone XL is positioned to become a secure and reliable North American source of nickel and cobalt for the stainless steel, electric vehicle, aerospace, and defense industries.

AWARUITE AT PIPESTONE XL: A SMELTER-FREE NICKEL-COBALT ALLOY (Ni₃Fe)

Awaruite is a naturally occurring, magnetic, sulphur-free nickel-iron-cobalt alloy (Ni₃Fe) containing approximately 77% nickel. Because it already exists in a metallic state, awaruite can be concentrated without smelting, roasting, or high-pressure acid leaching. Mineralogical and electron microprobe analysis at the Company’s RPM Zone has confirmed the awaruite averages 77.62% nickel and 1.69% cobalt, with grades as high as 86.68% nickel and 6.05% cobalt⁵.

Initial metallurgical test work using the Company’s ONSHORE MAX™ (Magnetic Alloy eXtraction) process upgraded rock samples from the project’s RPM Zone into a high-grade alloy concentrate averaging 67.4% nickel and grading up to 71.9% nickel and 1.76% cobalt⁶. Low-intensity magnetic separation first produced a magnetic concentrate grading approximately 1.6% nickel, which flotation then upgraded to the final concentrate. By comparison, a typical nickel concentrate grades 10% to 15% nickel, according to the Nickel Institute. This concentrate can move directly to downstream battery chemical refining or the manufacture of specialty alloys and stainless steel.

The absence of sulphur reduces acid mine drainage risk and related permitting challenges, positioning Pipestone XL to supply North American industries including stainless steel, electric vehicles, aerospace, and defence.

Figure 2: USGS quote on awaruite nickel-iron-cobalt alloy.⁷

The gross proceeds of the Offering will be used to incur eligible “Canadian exploration expenses” that qualify as “flow-through mining expenditures,” as those terms are defined in the Income Tax Act (Canada) (the “Qualifying Expenditures”), in connection with the exploration programs described above at the Company’s Pipestone XL Nickel-Cobalt Alloy Project and exploration activities at its Ophiolite X Project in Newfoundland. The Company will incur the Qualifying Expenditures on or before December 31, 2027 and renounce them in favour of subscribers effective December 31, 2026.

All securities issued in connection with the Offering are subject to a statutory hold period of four months and one day, expiring on February 6, 2027, under applicable Canadian securities laws. The Offering remains subject to final acceptance by the Exchange.

No finder’s fees were paid in connection with the Offering.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any applicable state securities laws, and may not be offered or sold within the United States or to U.S. persons unless registered under the U.S. Securities Act and applicable state securities laws, or an exemption from such registration is available.

INVESTOR INFORMATION

The Company’s common shares trade on the TSX Venture Exchange under the symbol “FAN”, on the OTCQB under the symbol “FANCF”, and on several German exchanges, including Frankfurt and Tradegate, under the symbol “P210”. Investors can get updates about First Atlantic by signing up to receive news via email and SMS text at www.fanickel.com.

FOR MORE INFORMATION

First Atlantic Investor Relations, Robert Guzman. Tel: +1-844-592-6337 | Email: rob@fanickel.com

QUALIFIED PERSON

Adrian Smith, P.Geo., a director and the Chief Executive Officer of the Company, is a qualified person as defined by NI 43-101. The qualified person is a member in good standing of the Professional Engineers and Geoscientists Newfoundland and Labrador (PEGNL) and is a registered professional geoscientist (P.Geo.). Mr. Smith has reviewed and approved the technical information disclosed herein.

ABOUT FIRST ATLANTIC NICKEL & COBALT CORP.

First Atlantic Nickel & Cobalt Corp. (TSXV: FAN | OTCQB: FANCF | FSE: P210) is a critical mineral exploration company in Newfoundland and Labrador developing the Pipestone XL Nickel-Cobalt (Ni-Fe-Co) Alloy Project. The project spans the entire 30-kilometre Pipestone Ophiolite Complex, where multiple zones, including RPM, Alloy Max, Super Gulp, Atlantic Lake and Chrome Pond, contain awaruite (Ni₃Fe), a naturally occurring magnetic nickel-iron-cobalt alloy of approximately 77% nickel with no sulphur and no sulphides, along with secondary chromium mineralization. Awaruite’s sulphur-free composition removes acid mine drainage risk, while its magnetic properties enable processing through magnetic separation and flotation, eliminating the electricity requirements, emissions and environmental impacts of conventional smelting, roasting or high-pressure acid leaching, while reducing dependence on overseas nickel processing infrastructure.

The U.S. Geological Survey recognized awaruite’s strategic importance in its 2012 Annual Report on Nickel⁸, noting that these deposits may help alleviate prolonged nickel concentrate shortages since the natural alloy is much easier to concentrate than typical nickel sulphide. In 2026, initial metallurgical test work using the Company’s ONSHORE MAX™ (Magnetic Alloy eXtraction) process upgraded RPM Zone material into a high-grade alloy concentrate averaging 67.4% nickel and grading up to 71.9% nickel and 1.76% cobalt, demonstrating a smelter-free, mine-to-refinery pathway. First Atlantic is a member of the U.S. Defense Industrial Base Consortium. The Company is also advancing a parallel geologic hydrogen initiative at Pipestone XL, where the same serpentinization process that formed awaruite also generates natural hydrogen, and has signed a letter of intent with VEMA Hydrogen to jointly develop low-carbon Engineered Mineral Hydrogen (EMH) through a proposed 50/50 joint venture. The Pipestone XL project is located near existing infrastructure with year-round road access and proximity to hydroelectric power, providing favorable logistics for exploration and future development and strengthening First Atlantic’s role to establish a secure and reliable source of North American nickel and cobalt production for the stainless steel, electric vehicle, aerospace, and defense industries. This mission gained importance when the U.S. added nickel to its critical minerals list in 2022, recognizing it as a non-fuel mineral essential to economic and national security with a supply chain vulnerable to disruption.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward looking statements

Certain information contained in this news release constitutes “forward-looking information” or “forward-looking statements” within the meaning of applicable Canadian securities legislation (collectively, “forward-looking information”). Forward-looking information is often identified by words such as “anticipates,” “believes,” “expects,” “intends,” “plans,” “may,” “will,” “potential,” and similar expressions.

Forward-looking information in this news release includes statements regarding: final acceptance of the Offering by the Exchange; the intended use of proceeds, the qualification of expenditures as Canadian exploration expenses and flow-through mining expenditures, the incurrence of those expenditures by December 31, 2027 and their renunciation in favour of subscribers effective December 31, 2026; the scope, timing and anticipated results of exploration and metallurgical programs at the Pipestone XL Nickel-Cobalt Alloy Project and Ophiolite X Project, including district-scale drilling, the development of an exploration access road toward the historic Atlantic Lake Zone and exploration and bedrock stripping along its route; expansion and infill drilling at the Alloy Max and RPM Zones, drilling of previously untested targets and the identification of new drill targets; the Company’s aim to develop a multi-pit resource at the Pipestone XL Nickel-Cobalt Alloy Project; the potential capabilities, scalability and benefits of the ONSHORE MAX™ process; the potential to concentrate awaruite without smelting, roasting or high-pressure acid leaching; the suitability of concentrates for downstream refining and the manufacture of battery chemicals, specialty alloys and stainless steel; potential environmental and permitting benefits; and the potential for Pipestone XL to supply North American industrial markets.

This forward-looking information is based on management’s current expectations and assumptions, including that required regulatory approvals will be obtained; planned expenditures will satisfy applicable tax requirements and be incurred and renounced within the specified timelines; necessary permits, personnel, contractors, equipment and laboratory capacity will be available; exploration and metallurgical programs can be completed within anticipated budgets and schedules; the exploration access road can be developed along the planned route within anticipated budgets and schedules; further testing will support the applicability of initial metallurgical results to representative project material and larger-scale operations; any resulting concentrates will meet relevant downstream processing and customer specifications; and that further environmental studies will support the anticipated environmental benefits.

Forward-looking information is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These include failure to obtain regulatory approvals or complete additional financing; changes in market conditions, commodity prices, costs or the availability of financing; failure to incur sufficient qualifying expenditures within the required period, adverse tax determinations or changes in tax laws or their interpretation; exploration results that do not support anticipated mineralization or expansion targets; exploration results that do not support the delineation of mineral resources; permitting, access, cost or construction delays affecting development of the exploration access road; geological and metallurgical variability; the preliminary nature of test results and the risk that such results cannot be replicated at larger scale or achieved economically; concentrate impurities, recovery limitations or failure to meet downstream specifications; permitting delays, environmental liabilities and findings that differ from anticipated environmental benefits; operational, weather, equipment, contractor and laboratory delays; and other risks described in the Company’s continuous disclosure filings available on SEDAR+ at www.sedarplus.ca.

Initial metallurgical results do not establish commercial viability or guarantee future recoveries, concentrate quality or processing performance. There can be no assurance that the anticipated exploration, processing, environmental or commercial outcomes will be achieved.

Although management considers its expectations and assumptions reasonable as of the date of this news release, forward-looking information is not a guarantee of future performance. Readers are cautioned not to place undue reliance on it. Except as required by applicable securities laws, the Company undertakes no obligation to update forward-looking information to reflect subsequent events, circumstances or changes in expectations.

¹ https://fanickel.com/20260608-vema-hydrogen-and-first-atlantic-nickel-cobalt-sign-loi-to-develop-engineered-mineral-hydrogen-at-pipestone-xl-awaruite-project-in-newfoundland
² https://fanickel.com/20260115-first-atlantic-nickel-highlights-relevance-of-pipestone-xl-awaruite-nickel-cobalt-alloy-discovery-to-address-u-s–critical-mineral-supply-chain-vulnerabilities-identified-in-january-14-2026-white-house-proclamation
³ https://fanickel.com/20260331-first-atlantic-nickel-announces-acceptance-into-defense-industrial-base-consortium-dibc—pipestone-xl-smelter-free-nickel-cobalt-alloy-project-addresses-midstream-smelting-bottleneck-in-u-s–defense-supply-chain
⁴ https://fanickel.com/20260619-first-atlantic-nickel-cobalt-highlights-g7-leaders-declaration-on-critical-minerals-g7-names-nickel-one-of-only-two-pilot-minerals-for-a-new-allied-traceability-framework-moves-to-mobilize-equity-investment-and-offtake-and-establishes-a-critical-
⁵ https://fanickel.com/20260521-first-atlantic-nickel-cobalt-reports-electron-microprobe-analysis-returning-77-62-nickel-and-1-69-cobalt-in-awaruite-at-the-rpm-zone-pipestone-xl-project-a-rare-naturally-magnetic-ni-fe-co-high-grade-alloy-mineralogically-capable-of-bypassing-mid
⁶ https://fanickel.com/20260624-first-atlantic-nickel-cobalt-produces-high-grade-alloy-concentrate-up-to-71-9-nickel-and-1-76-cobalt-from-its-pipestone-xl-nickel-cobalt-alloy-project-using-its-first-ever-onshore-max-magnetic-alloy-extraction-recovery-concentration-process-unvei
⁷ https://d9-wret.s3.us-west-2.amazonaws.com/assets/palladium/production/mineral-pubs/nickel/mcs-2012-nicke.pdf
⁸ https://d9-wret.s3.us-west-2.amazonaws.com/assets/palladium/production/mineral-pubs/nickel/mcs-2012-nicke.pdf

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/448ace60-5570-46e8-a872-d671bdc932ad
https://www.globenewswire.com/NewsRoom/AttachmentNg/c98b10b1-2d62-453b-9af8-3491ba8675ae